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India has the second highest number of HIV-1 infected people next to South Africa. The predominant proportion of HIV-1 circulating in India
is of subtype C origin, with a small fraction made up of subtypes A and B. In this report, we describe the construction and characterization of the
first full-length infectious molecular clone p1579A-1 HIV-1, from an HIV-1 subtype A infected person from India, using long PCR and successive
ligation of the amplimers. Phylogenetic analysis of the sequence of the entire proviral DNA and LTR confirmed p1579A-1 to be an HIV-1 subtype
A. Analysis of the env gene of p1579A-1 showed a conserved GPGQ motif and the absence of basic amino acids at positions 11 and 25 suggesting
CCR5 coreceptor usage. Analysis of env N-linked glycosylation sites revealed fewer sites in the V1 region of envelope compared to other subtype
A. Transcription factor binding site analysis of the LTR sequences identified conserved as well as unique transcription factor binding sites (TFBS)
in p1579A-1. This infectious clone of HIV-1 can be useful to study the molecular mechanism of dominance of subtype C in India.
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among female commercial sex workers (John et al., 1987;
Simoes et al., 1987) Since then, HIV-1 has spread rapidly
throughout the country and has been reported in nearly every
major city. Today, India has the second largest number of HIV-
1 infected individuals in the world next to South Africa
(UNAIDS and W.H.O., 2004). Genetic analyses of HIV-1
sequences circulating in different parts of India have shown
that the predominant proportion of HIV-1 circulating in India is
of subtype C origin with a small fraction of subtypes A and B
(Cassol et al., 1996; Delwart et al., 1998; Maitra et al., 1999;
Mandal et al., 2000, 2002; Shankarappa et al., 2001; Tripathy
et al., 1996). Furthermore, phenotypic and genotypic analyses
of env sequences of HIV-1 in India indicate that they are CCR50042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: pgupta1@pitt.edu (P. Gupta).tropic with non-syncytium inducing phenotype even when they
are isolated from late stage of infection (Cecilia et al., 2000;
Shankarappa et al., 2001). We have recently analyzed subtype
C sequences from India and then compared this set of
sequences to subtype C sequences sampled from Botswana,
Burundi, South Africa, Tanzania, and Zimbabwe. Overall,
HIV-1 type C sequences from different parts of India were
more closely related to each other (10%) than to subtype C
sequences from Botswana, Burundi, South Africa, Tanzania,
and Zimbabwe (15–21%) (Shankarappa et al., 2001). These
results indicate that subtype C sequences in India are distinct
from subtype C sequences sampled from other countries.
Over the course of the HIV-1 epidemic in India, and
regardless of geographical area, subtype C has consistently
accounted for 90–95% of infections with subtypes A, B, and
others accounting for the remaining 5–10% (Cassol et al.,
1996; Delwart et al., 1993; Jameel et al., 1995; Tripathy et al.,6) 328 – 336
www.e
M.A. Rodriguez et al. / Virology 345 (2006) 328–336 3291996; Tsuchie et al., 1995). This together with the fact HIV-1
isolated from different parts of India at different times are
closely related (Shankarappa et al., 2001) suggests that the
preponderance of subtype C viruses over other subtypes is
most probably not due to new and continual introductions of
HIV-1 subtype C into the country or to recent immigration or
representative of a cluster of isolated individuals. It is possible
that the disproportionate distribution of HIV-1 subtypes in
India may be due to one or a combination of factors including
founder effect, replication fitness, and transmission efficiency.
In order to elucidate the molecular dynamics of HIV-1 subtype
distribution in India, it is important to have an infectious
molecular clone, such as subtype A, from India. Reports of
subtype A viruses in India date back to 1991 (Cassol et al.,
1996) and since then they have been periodically reported in
various studies (Ljungberg et al., 2002; Sahni et al., 2002;
Shankarappa et al., 2001). To date, there are no sequence data
of the complete genome of an HIV-1 subtype A nor does a
replication competent infectious molecular clone of subtype A
exist. Here, we report the construction of a full-length
infectious molecular clone of subtype A HIV-1 from India
and delineation of its complete genomic sequence.
Results and discussion
From the molecular epidemiological data, it is expected that
very few subjects will be infected with subtype A HIV-1.
Therefore, we have performed virus isolation from a number of
HIV-1 infected subjects and determined their subtype specificity.
The infected subjects for this study were recruited from Calcutta,
the major eastern city of India. A summary of patient
characteristics is shown in Table 1. HIV-1 was isolated fromTable 1
Characteristics of HIV-1 infected subjects from India
Patient
ID#
Age Sex Clinical Symptoms CD4
Count
Subtype
2145 33 F Asymptomatic 678/ul ND
1577 18 F Asymptomatic 814 C
2161 53 M Asymptomatic 427 ND
1590 16 F Weakness, anorexia 736 ND
2024 25 F Asymptomatic 350 C
1310 25 F Abdomen pain, diarrhea 343 C
1581 21 F Fever, cough, weakness 377 C
1580 18 F Asymptomatic 810 C
1540 20 F Total body pain,
menstrual problems
640 ND
1579 16 F Asymptomatic 477 A
1443 34 F Weakness 702 C
2167 25 F Abdomen pain, leuchorrhoea 255 C
1585 21 F Weakness 331 C
2163 25 F Weakness, anorexia 275 C
2177 18 F Cold and cough, weakness 193 C
1583 18 F Asymptomatic 945 C
1521 30 F Weakness, blood pressure
31/87
221 ND
2114 ND ND Asymptomatic ND C
1451 26 F Headache, cough, weight
loss, weakness
291 ND
ND—not determined.these patients by coculturing their PBMC with PHA-stimulated
CD8 depleted normal donor PBMC as described previously
(Balachandran et al., 1991; Balachandran et al., 1988).
Production of virus was monitored by HIV-1 p24 production
in the culture supernatant. Following 30 to 40 days of
cultivation, chromosomal DNAwas extracted from the infected
cell pellets. The DNAwas then used to determine the subtypes of
HIV-1 isolates using a heteroduplex mobility assay (HMA) kit
obtained through the NIH AIDS Repository (Bachmann et al.,
1994; Delwart et al., 1993, 1995). In this assay, a nested PCR
reaction was employed which in the first round amplified a
¨1.25-kb-long amplimer encompassing the V1–V5 region of
the HIV-1 envelope gene from proviral DNA. The 1.25-kb DNA
was then used as a template in the second round of PCR to
amplify a ¨0.7-kb C2–V5 envelope gene fragment. Similar
nested PCR primer pairs were also used for amplification of the
C2–V5 region from reference plasmids carrying HIV-1 subtype
A, B, and C env sequences. Nested PCR products from each of
the reference plasmids and the unknown were then combined,
denatured and re-annealed. Subtypes were assigned based on the
mobility of heteroduplexes on a non-denaturing polyacrylamide
gel. Among the 19 HIV-1 positive Indian isolates tested, one,
1579, was found to be a subtype A (Table 1). Subtypes were
further verified by sequencing the 0.7-kb PCR products
followed by its blast analysis at the Los Alamos HIV-1 Database
(data not shown). Proviral DNA from this isolate (1579A) was
then used to construct the subtype A infectious molecular clone.
To construct the full-length molecular clone, long PCR was
performed using a high fidelity polymerase and chromosomal
DNA from HIV-1 1579A infected PBMC. Three overlapping
subgenomic fragments of 2.5 kb: 5VLTR-pol, 6.2 kb: gag-env,
and 2.7 kb: env-3VLTR were generated. These three fragments
were cloned into pCR-Blunt II-Topo cloning vectors (Invitro-
gen) resulting in plasmids A, B, and C, respectively (Fig. 1).
Plasmids A and B were digested with unique restriction
enzymes AhdI and FseI, and the resulting fragments were
ligated to generate plasmid D containing a 7.6-kb fragment of
1579A genome. Plasmids C and D were then digested with
unique restriction enzymes DraIII and SnaBI, and the resulting
fragments were ligated to generate the full-length infectious
molecular clone, p1579A. Our cloning strategy exploited the
pUC origin of replication and kanamycin resistance gene
within the cloning vector such that the fragments being ligated
together contained either one or the other of these features. This
technique significantly lowered the background of our ligation
products and facilitated cloning of these large fragments.
To validate the presence of the entire HIV-1 genome in
p1579A clones, PCR was performed on three separate clones
using gag, pol, and env gene specific primers. Each of the three
clones produced amplimers of correct size, 0.9 kb, 1 kb, and
0.7 kb, corresponding to HIV-1 gag, pol and env genes,
respectively (Fig. 2). The intactness of these three clones
gained further support by the analysis of the digestion pattern
with NotI restriction enzyme which cleaves outside of the HIV-
1 subtype A genome on either side. An approximately 10-kb
band corresponding to full-length HIV-1 DNA and a 3.8-kb
band corresponding to the plasmid vector were observed for
Fig. 1. Construction of an HIV-1 subtype A infectious molecular clone. (A) PCR and cloning of three overlapping subgenomic fragments of 1579A genome. (B)
Cloning strategy. Each of the plasmids was cut with unique restriction enzymes and the products ligated together to recover a complete full-length clone of 1579A.
M.A. Rodriguez et al. / Virology 345 (2006) 328–336330each clone that was digested (data not shown). One of these
three clones, p1579A-1, was used in subsequent biologic and
genetic studies.
The infectivity of p1579A-1 was examined by transfection
of human endothelial kidney (HEK) 293T cells. Forty eightFig. 2. Validation of whole genome clone using HIV-1 PCR primers for gag,
pol and env genes. M—marker. Lanes 1, 2, 3; gag, pol, env (respectively) PCR
products for clone #1. Lanes 4, 5, 6; gag, pol, env (respectively) PCR products
for clone #2. Lanes 7, 8, 9; gag, pol, env (respectively) PCR products for clone
#3. Lanes 10, 11, 12; gag, pol, env (respectively) PCR products for positive
control of chromosomal DNA from 1579-infected PBMC.hours after transfection, filtered culture supernatant was used
to infect CD8 depleted PBMC (Kalia et al., 2003). Virus
growth was monitored by measuring HIV-1 p24 antigen in
culture supernatant. An infectious molecular clone of HIV-1
subtype C of Indian origin, pIndieC1 (Mochizuki et al., 1999)
was used as a positive control for transfection. Results shown
in Fig. 3A indicate that p1579A-1 is able to produce
replication competent HIV-1.
To characterize the growth properties of HIV-1 p1579A-1,
CD8 depleted PBMC were infected with p1579A-1 virus
(equivalent to 21ng of p24) collected from transfected culture
supernatant and an equivalent p24 value of the parental HIV-1
subtype A isolate. Kinetics of viral replication was deter-
mined by measuring HIV-1 p24 antigen in culture superna-
tant. Fig. 3B shows that p1579A-1 cloned virus has similar
growth properties as the parental isolate. However, the
parental isolate produced slightly higher p24 values than
p1579A-1.
To determine the coreceptor usage of p1579A-1 cloned
virus, U87.CD4 cells expressing either the CXCR4 or CCR5
coreceptors were infected with virus containing supernatant
equivalent to 30ng of HIV-1 p24 antigen. Virus growth was
Fig. 3. (A) Transfection– infection of p1579A-1 DNA. HEK293T cells were first transfected with p1579A-1 or the control pIndieC1 DNA. Two days after
transfection, culture supernatant was then used to infect CD8 depleted PBMC. Production of HIV-1 p24 antigen on each day sampled is shown for p1579A-1 and the
control pIndieC1. (B) Replication kinetics of p1579A-1. CD8 depleted PBMC were infected with 21ng of HIV-1 p24 equivalent virus supernatant of p1579A-1 or
the parental isolate, 1579A. Virus growth was monitored by measuring HIV-1 p24 antigen in the culture supernatant every 2 days.
M.A. Rodriguez et al. / Virology 345 (2006) 328–336 331monitored by measuring p24 antigen in culture supernatant.
p1579A-1 HIV-1 replicated more efficiently in U87.CD4 cells
expressing CCR5 than CXCR4, indicating that p1579A-1 virus
is an R5 tropic virus (Table 2). Consistent with CCR5
coreceptor usage, p1579A-1 HIV-1 was found to be non-
syncytia inducing (NSI), due to its inability to form syncytia in
MT2 cells (data not shown).Table 2






CCR5 CXCR4d CCR5 CXCR4e CCR5f CXCR4
2 183 276 2,276 601 338 >200,000
4 705 210 99,275 650 425 >200,000
6 3480 220 ND ND ND ND
8 12,770 280 ND ND ND ND
10 33,625 300 ND ND ND ND
a,b,c HIV-1 p24 antigen production (pg/ml) in U87.CD4.CCR5 or
U87.CD4.CXCR4 expressing cells.
d,e,f An increase in p24 value of at least 3-fold over the day 2 value is
considered positive HIV replication.
ND—not determined.The complete sequence of the proviral DNA of p1579A-1
was determined by primer walking along the entire genome.
The sequences were verified using the HIV-1 Sequence Locator
tool at the Los Alamos HIV-1 sequence database and then
manually joined. The full-length genome of p1579A-1 is 9699-
bp long. All reading frames of this clone were found to be
open. The entire genome was subjected to HIV-1 recombina-
tion analysis at the Los Alamos Sequence Database and was
not found to be an HIV-1 recombinant. The complete genome
of p1579A-1 and the long terminal repeat (LTR) were aligned
with HIV-1 group M subtype reference sequences obtained
from the Los Alamos HIV-1 database. Phylogenetic analysis of
both the complete genome and the LTR showed that 1579A
clusters within the HIV-1 subtype A lineage (Fig. 4).
The envelope gene is important for viral attachment,
infectivity, and coreceptor usage. We analyzed the envelope
gene by aligning the predicted amino acid sequence of p1579A-
1 with those of the consensus sequence of reference subtypes A1
and A2 and pIndieC1. The characteristic GPGQ motif at the
crown of the V3 loop was conserved in all sequences (Fig. 5).
Consistent with earlier findings of CCR5 coreceptor usage and
an NSI phenotype, there was an absence of basic amino acids at
positions 11 and 25 in p1579A-1 (Fig. 5). This was also true for
Fig. 4. Phylogenetic analysis of p1579A-1. (A) Neighbor-joining Jukes Cantor unrooted tree showing the phylogenetic relationship of the complete genomic
sequence of p1579A-1 to HIV-1 group M reference subtypes. (B) Maximum likelihood unrooted tree showing the phylogenetic relationship of p1579A-1 long
terminal repeat (LTR) sequence to the consensus (CONS) sequence of HIV-1 group M LTR. All HIV-1 group M reference sequences were obtained from the Los
Alamos HIV database.
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Fig. 5. Molecular characterization of HIV-1 p1579A-1 envelope gene. Amino acid alignment of p1579A-1, reference subtype A1 and A2 (subgroups of HIV-1 group
M, subtype A) consensus sequences obtained from Los Alamos HIV-1 database and IndieC1 envelope gene. N—predicted N-linked glycosylation site. The GPGQ
motif is surrounded by solid box. Positions 11 and 25 are represented by an asterisk (*).
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analysis of potential N-linked glycosylation sites did not show
any major differences between p1579A-1 and reference subtype
A1 or A2 obtained from the Los Alamos HIV database or
pIndieC1. The number of predicted potential sites ranged from
27 to 31, with pIndieC1 having the most, 31 and p1579A-1
having 29. Variations in the locations and number of sites were
seen predominantly in the variable regions V1, V2, V4, and V5.
Only one potential site was predicted for p1579A-1 between
positions 131 and 150 of the V1, region whereas at least 2 sites
were predicted for other subtype A’s and 3 were predicted for
IndieC1 (Fig. 6B). Lack of potential N-linked glycosylation
sites in this region is probably due to a 14-amino acid deletion in
this region. Absence of glycans in this region could have an
effect on CD4-gp120 interaction and viral entry (Chen et al.,
2001; Kwong et al., 1998).
The long terminal repeat (LTR) is known to contain essential
elements that control HIV-1 transcription and hence replication.
As a first step to explore biological differences between
subtypes from India, we compared the LTR of p1579A-1 with
the LTR of pIndieC1 by performing a transcription factor
binding site (TFBS) prediction analysis. Several differences
were observed in the number of TFBS between subtypes A and
C (Fig. 6). Most notably, both p1579A-1 and pIndieC1 were
found to contain two NF-kappa B binding sites. This is in
contrast to HIV-1 subtype C of African origin which has been
shown to carry three functional NF-kappa B enhancers. This is
not unusual, since Indian subtype C has been shown to be
genetically distinct from other HIV-1 subtype C around the
world (Shankarappa et al., 2001). Furthermore, pIndieC1 andnot p1579A-1 has the binding sites for GATA-binding factor 3
(GATA) and octamer-binding factor 1 (Oct1). GATA 3 is a
member of a family of transcriptional activating proteins and is
expressed in T lymphocytes. In vitro studies have shown
enhanced HIV-1 LTR-directed transcription in the presence of
this protein (Yang and Engel, 1993). Octamer-binding proteins
(Oct) have been reported to both positively and negatively
regulate the expression of a variety of genes (Zhang et al., 2004;
Liu and Latchman, 1997). In vitro studies have shown Oct-1 to
either repress LTR-directed transcription of HIV-1 in fibroblasts
(Liu and Latchman, 1997) or to have no effect on HIV-1
transcription in primary CD4 T Cells (Zhang et al., 2004).
Finally, p1579A-1 but not pIndieC1 has the binding site for GC
Box elements which have been reported to be a component of
Vpr-mediated LTR activation (Kuiken et al., 2001). It can be
hypothesized that the presence or absence of these binding sites
in the LTR of subtypes C and A may be responsible for
differences in replication efficiency, resulting in the higher
prevalence of subtype C over other subtypes of HIV-1 in India.
Further studies are necessary to evaluate this hypothesis.
In conclusion, out of 19 HIV-1 Indian isolates, only one was
found to be a subtype A. This finding is consistent with the low
frequency (5–10%) of subtype A prevalence in India. From
this HIV-1 subtype A isolate the molecular clone p1579A-1
was constructed. This clone was found to be replication
competent in CD8 depleted PBMC and CCR5 tropic as
determined by genotypic and phenotypic analysis. Sequence
analysis of p1579A-1 indicate it to be phylogenetically linked
to HIV-1 subtype A. p1579A-1 represents the first infectious
molecular clone of HIV-1 subtype A which replicates in
Fig. 6. Analysis of HIV-1 long terminal repeat (LTR). (A) Chart listing predicted transcription factor binding sites. Values in each column represent the number of
sites predicted for each transcription factor binding site. (B) Schematic representation of predicted TFBS within the LTRs of 1579A (upper) and IndieC1 (lower).
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subtype A HIV-1 will be useful for the study of replication
dynamics and evolution of subtypes in India. Furthermore, its
full genomic sequence will be important for characterizing
other HIV-1 subtype A around the world.
Materials and methods
Virus cultures
PBMC from 19 HIV-1 positive Indian patients was cultured
in the presence of phytohemagglutin (PHA)-stimulated, CD8
depleted normal donor PBMC in RPMI 1640 media supple-
mented with IL-2 as described previously (Balachandran et al.,
1988; Balachandran et al., 1991). Production of virus was
monitored by HIV-1 p24 production in the culture supernatant.
Virus was harvested every 5 days for 40 days. 10–20 million
cultured cells were pelleted and stored at 80 -C for DNA
isolation and subtyping.
DNA isolation and HIV-1 env subtyping by HMA
High molecular weight chromosomal DNA was purified
from cultured cell pellets using PUREGENE DNA purification
kit. The DNA was then subjected to a heteroduplex mobility
assay (HMA), as described previously (Delwart et al., 1993).ED5/ED12 primers were used to PCR amplify the V1–V5
region of the envelope gene followed by a nested PCR
amplification of the C2–V5 region using primers DR7/DR8.
The cycling conditions for both primer pairs were as follows: 3
cycles of 94 -C for 1 min, 55 -C for 1 min, 72 -C for 1 min,
followed by 32 cycles of 94 -C for 15 s, 55 -C for 45 s, 72 -C
for 1 min. Final extension was at 72 -C for 5 min. DR7/DR8
PCR products from each of the reference plasmids and the
unknown HIV-1 were then combined, denatured at 99 -C for 5
min, and then re-annealed on wet ice for 10 min. Hetero-
duplexes were resolved on a 5% non-denaturing polyacryl-
amide gel at 250 V for 3 h. The gel was then stained with
ethidium bromide and visualized in a phosphoimager.
Construction of the full-length infectious molecular clone
The entire 1579A genome was amplified in three fragments.
Long PCR was performed using the high fidelity AccuPrime
Pfx DNA polymerase (Invitrogen) and 1 Ag of chromosomal
DNA from HIV-1 1579A infected PBMC. Three overlapping
subgenomic fragments of 2.5 kb, 5VLTR-gag, 6.2 kb, gag-env,
and 2.7 kb, env-LTR3V, were generated using PCR primers
shown in Table 3. The cycling conditions were as follows: 1
cycle of 95 -C for 2 min. Followed by 10 cycles of 94 -C for 10
s, 55 -C for 30 s and 66 -C for 2 min, followed by 25 cycles of
94 -C for 15 s, 55 -C for 30 s and 66 -C for 2 min. Final
Table 3
Primers used for amplification of HIV-1 subtype A genome
Fragment
length (kb)
Position Primer Sequence (5VY3V)
2.5 5VLTR-pol U3XhoI ATT ACT CGA GTG GAT
GGG TTA ATT
HIV-1Pol1 ACT GGT ACA GTC TCA
ATA GGA CTA ATT G
6.2 gag-env SK145 AGT GGG GGG ACA TCA
AGC AGC CAT GCA AAT
DR8 GGG ACA ATT GGA GAA
GTG
2.7 env-3VLTR DR7 CAA CTG CTG TTA AAT
GGC AGT CTA GC
New LTR
3V NotI
ATA AGC GGC CGC CCA
CTG CTA GAG ATT T
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increased by 5 s every additional cycle. Annealing tempera-
tures for 2.5 kb, 6.2 kb and 2.7 kb were 50 -C, 55 -C and 57
-C, respectively. PCR products were gel purified using Mo Bio
Laboratories DNA purification kit and then cloned into pCR-
Blunt II TOPO vectors (Invitrogen) resulting in plasmids A, B,
and C, respectively. The plasmid A carrying the 2.5-kb HIV-1
DNA fragment and the plasmid B carrying the 6.2-kb HIV-1
DNA fragment were digested with unique restriction enzymes.
The 4.4-kb fragment from the plasmid Awas ligated to the 6.7-
kb fragment from the plasmid B to generate a plasmid D that
contained a 7.6-kb fragment encompassing the 5VLTR-env
region of the 1579A HIV-1 genome. The plasmid C carrying
the 2.7-kb HIV-1 DNA fragment and plasmid D were then
digested with unique restriction enzymes. The 9.6-kb fragment
from the plasmid D was ligated to the 3.9-kb fragment from the
plasmid C to generate a plasmid that contained the complete
full-length HIV-1 proviral genome of 1579A and was
designated p1579A.
Transfection, replication kinetics, coreceptor usage, and MT2
assay
HEK293T cells (ATCC) were maintained in DMEM
supplemented with 15% FBS, 1% l-glutamine, 1% penicil-
lin–streptomycin, 1 Ag/ml puromycin and 300 Ag/ml G418.
293T cells that were grown to 90–95% confluency were
transfected with 14 Ag of p1579A-1 DNA or 35 Ag of control
plasmid pIndieC1 with Lipofectamine 2000 reagent (Invitro-
gen). Transfected HEK293T cells were cultured in 15% D-
MEM media for 48 h. After 48 h, supernatant from transfection
cultures was passed through a 0.45 Am filter and added to 5
million PHA stimulated CD8 depleted PBMC treated with 5
Ag/ml polybrene for 1 h in RPMI media supplemented with IL-
2. Cultures were maintained at 37 -C. Cultures were tested for
the presence of p24 antigen every 2–3 days and fed with 2.5
million PHA stimulated and polybrene treated CD8 depleted
PBMC every 7 days.
To determine the coreceptor usage of p1579A-1 virus,
U87.CD4 cells (NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH) were infected as
described (Bjorndal et al., 1997) Briefly, U87.CD4 cellsexpressing either the CXCR4 or CCR5 chemokine receptors
were seeded in duplicate in a 24-well microtiter plate at a
concentration of 250,000 cells/well in a final volume of 500
Al 15%D-MEM. The cells were incubated at 37 -C until
they became 90% confluent. The media were removed from
confluent cells, and the cell monolayer was washed with
500 Al PBS. Approximately 0.5 ml (30 pg p24 equivalent)
of p1579A-1 or the control HIV-1 BAL or IIIB was added
to duplicate wells of U87.CD4.CCR5 and CXCR4 cells.
One set of wells for each coreceptor was left uninfected as
a negative control. An additional 0.5 ml of DMEM
containing 15% FCS was added to each plate, and the
plates were incubated at 37 -C for 24 h. After 24 h, the
supernatant was removed. The cells were rinsed with PBS
and incubated in 1 ml fresh DMEM supplemented with
15% FCS. HIV-1 p24 production in the supernatant was
monitored every 2 days.
To determine the replication kinetics of p1579A-1 cloned
virus 10 million PHA-stimulated CD8 depleted PBMC treated
with 5 Ag/ml polybrene for 1 h were infected with
approximately 30 ng equivalent HIV-1 p24 virus of either
cloned virus or the parental isolate. The infections were
carried out for 2 h, with shaking every 30 min at 37 -C. After
the 2 h, the virus supernatant was removed, and the cells were
washed and cultured at 37 -C in RPMI 1640 medium
containing 20% FCS and 5% IL-2. Virus growth was
monitored every 2 days by p24 antigen production in the
culture supernatant.
MT2 assay to measure syncytia inducing activity of HIV-1
was performed as described previously (O’Marro et al., 1992).
Sequencing, phylogenetic analysis and molecular
characterization
The entire viral genome was sequenced using an automated
sequencer. Sequences were manually joined and contiguous
sequence fragments were assembled using Vector NTI suite
(Informax, Oxford, UK). DNA and protein alignments were
constructed using CLUSTAL X alignment program of Vector
NTI. Consensus sequences and subtype reference sequences
used for alignments were obtained from the Los Alamos HIV-1
database.
Phylogenetic analyses of the entire genome sequence
were constructed by the neighbor-joining method of Jukes
Cantor corrected distances (protein, total mean character
corrected distances) with the optimality criterion set to
distance as measured in PAUP. Statistical significance of
branchings and various clustering were assessed by bootstrap
re-sampling of 1000 pseudoreplicates on the complete data
set. The trees were edited for publication using Treeview68K
version 1.5. Phylogenetic analyses of LTR sequences were
conducted through the construction of maximum likelihood
trees as measured in PAUP. Statistical significance of
branchings and various clustering were assessed by bootstrap
re-sampling of 1000 pseudoreplicates on the complete data
set. The trees were edited for publication using Treeview68K
version 1.5.
M.A. Rodriguez et al. / Virology 345 (2006) 328–336336N-glycosylation site analysis was performed at the Los
Alamos HIV-1 database. Transcription factor binding site
predictions were performed using MatInspector.
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